fda announcement semaglutide Semaglutide: The Drug of Today and a Steppingstone to Tomorrow FDA says Wegovy and Ozempic

The research doesn't suggest harm from longer cycles, but periodic breaks are a reasonable precaution given limited long-term human data

Effects of Age, Body Mass Index (BMI), Gender, and Race Sitagliptin Based on a population pharmacokinetic analysis or a composite analysis of available pharmacokinetic data, BMI, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of sitagliptin

Circulating GLP-1 from diet and lifestyle has a half-life of 1-2 minutes before being inactivated in our bodies (Mozafariun et al 2025

Many patients find they naturally eat 3040% fewer calories during this peak window without feeling deprived, because semaglutide genuinely reduces hunger rather than forcing restriction

Trying to get a bargain on your GLP-1 medication might come with some added danger

What isnt retained is passed on to health care plan sponsors